StockData

Balchem vs Innospec

BCPC and IOSP side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCPC and IOSP compare

Balchem is the larger company, worth 2.8 times as much as Innospec ($5.4B against $2.0B).

Balchem grew revenue faster over the last twelve months (9.4% versus 2.9% for Innospec).

Both pay dividends: Balchem yields 0.56% and Innospec 3.4%.

Balchem scores higher on the StockData Score (19 against 13 for Innospec), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCPCIOSP
Size and price
Market cap$5.4B$2.0B
Share price$171.48$79.17
Change, 1 year9.2%5.9%
Change, 5 years3.8%−4.8%
Beta (5Y)0.121.08
Employees1,3522,450
StockData Score
Total score19 (better)13
Valuation score23 (better)
Growth score4 (better)1
Performance score5 (better)1
Health score66
Dividend score22
Valuation
P/E32.3×–
P/S4.9×1.1× (better)
P/B4.1×1.5× (better)
EV/EBITDA19.3×10.0× (better)
PEG2.39–
Fair value$149.11$92.52
Margin of safety−15.0%14.4% (better)
Growth
Revenue growth (TTM)9.4% (better)2.9%
Revenue growth, 5Y average8.1%8.3% (better)
Net income growth (TTM)14.5%–
EPS growth (TTM)16.2%–
EPS growth, 5Y average12.8%32.1% (better)
Profitability
Gross margin36.5% (better)27.5%
Operating margin20.7% (better)7.0%
Net margin15.4%–
Return on equity13.0%–
Return on invested capital14.3% (better)10.4%
Financial health
Debt / equity0.000.00
Current ratio2.472.78 (better)
Altman Z-score10.97 (better)4.88
Piotroski F-score9–
Dividends and buybacks
Dividend yield0.56%3.4% (better)
Payout ratio18.0%–
Years of dividend growth312 (better)
Dividend growth, 5Y average–10.5%
Buyback yield2.3% (better)1.2%
Shareholder yield2.9%4.7% (better)
Ownership
Held by institutions91.3%101%
Held by insiders0.72%1.6%
Insider net buying, 12 months−$2.2M−$874K (better)
Short interest, % of float1.6%1.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.